Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene

Dateline City:

NEW YORK

Celgene Acquisition Has Clear Strategic Rationale and Represents a Compelling Value Proposition
Bristol-Myers Squibb Has a Strong Track Record of Financial and Operational Outperformance
Board and Management Team Conducted a Robust Process and Diligence and Are Committed to a Successful Integration

NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today filed an investor
presentation with the Securities and Exchange Commission (SEC), and the
Board of Directors sent an open letter to the Company’s shareholders
regarding the previously announced definitive merger agreement with
Celgene Corporation (NASDAQ:CELG). The investor presentation is
available on www.bestofbiopharma.com.

Language:

English

Contact:

Media:Laura Hortas609-252-4587 [email protected] or Andy Brimmer / Dan KatcherJoele Frank, Wilkinson Brimmer Katcher212-355-4449 Investors:Tim Power609-252-7509 [email protected] or Dan BurchMacKenzie Partners, Inc.212-929-5748 [email protected]

Ticker Slug:

Ticker: BMY Exchange: NYSE

read more

Original Source